• Allergy, Asthma & Immunology Research
• /
• 제10권6호
• /
• pp.575-590
• /
• 2018

The prevalence of allergic disorders has dramatically increased over the past decade, particularly in developed countries. Apart from gastrointestinal disorders, neoplasia, genital and dermatological diseases etc., dysregulation of gut microbiota (dysbiosis) has also been found to be associated with increased risk of allergies. Probiotics are increasingly being employed to correct dysbiosis and, in turn, to modulate allergic diseases. However, several factors like strain variations and effector metabolites or component of them in a bacterial species can affect the efficacy of those as probiotics. On the other hand, host variations like geographical locations, food habits etc. could also affect the expected results from probiotic usage. Thus, there is a glaring deficiency in our approach to establish probiotics as an irrefutable treatment avenue for suitable disorders. In this review, we explicate on the reported probiotics and their effects on certain allergic diseases like atopic dermatitis, food allergy and asthma to establish their utility. We propose possible measures like elucidation of effector molecules and functional mechanisms of probiotics towards establishing probiotics for therapeutic use. Certain probiotics studies have led to very alarming outcomes which could have been precluded, had effective guidelines been in place. Thus, we also propose ways to secure the safety of probiotics. Overall, our efforts tend to propose necessary discovery and quality assurance guidelines for developing probiotics as potential immunomodulatory 'Pharmabiotics.'

• 식품과학과 산업
• /
• 제52권3호
• /
• pp.229-240
• /
• 2019

2002년 FAO와 WHO에 의하여 "적절한 양을 섭취했을 때 숙주(사람)의 건강에 이로운 작용을 하는 생균"으로 정의된 이래 프로바이오틱스는 연구적인 측면뿐 아니라 제품화를 통한 시장의 지속적인 성장을 거듭하여 기능성 식품의 매우 중요한 부분을 차지하고 있다. 최근에는 마이크로바이옴 연구에 힘입어 프로바이오틱스가 장 건강뿐 아니라 전신의 건강과 관련되어 다양한 역할이 밝혀지고 있으므로 더욱 다양한 형태 및 기능을 갖는 제품의 개발이 기대되고 있다. 아울러 국제적으로 경쟁력을 가지고 유통되기 위해서는 글로벌 기준에 맞는 품질관리를 통한 인증 등에 대한 노력이 필요하다. 본 논문에서는 프로바이오틱스의 새로운 정의, 프로바이오틱스의 국내외 관리기준, 효능의 균주 특이성, 마이크로바이옴과의 연관성, 시장 동향에 대하여 살펴보았다.

• Translational and Clinical Pharmacology
• /
• 제26권3호
• /
• pp.103-110
• /
• 2018

The human microbiome is known to play an essential role in influencing host health. Extracellular vesicles (EVs) have also been reported to act on a variety of signaling pathways, distally transport cellular components such as proteins, lipids, and nucleic acid, and have immunomodulatory effects. Here we shall review the current understanding of the intersectionality of the human microbiome and EVs in the emerging field of microbiota-derived EVs and their pharmacological potential. Microbes secrete several classes of EVs: outer membrane vesicles (OMVs), membrane vesicles (MVs), and apoptotic bodies. EV biogenesis is unique to each cell and regulated by sophisticated signaling pathways. EVs are primarily composed of lipids, proteins, nucleic acids, and recent evidence suggests they may also carry metabolites. These components interact with host cells and control various cellular processes by transferring their constituents. The pharmacological potential of microbiome-derived EVs as vaccine candidates, biomarkers, and a smart drug delivery system is a promising area of future research. Therefore, it is necessary to elucidate in detail the mechanisms of microbiome-derived EV action in host health in a multi-disciplinary manner.